Document is current
Any future updates will be listed below
-
Authors
Zhang, Diane
Segerstolpe, Åsa
Slyper, Michal
Waldman, Julia
Murray, Evan
Strasser, Robert
Watter, Jan
Cohen, Ofir
Ashenberg, Orr
Abravanel, Daniel
Jané-Valbuena, Judit
Mages, Simon
Lako, Ana
Helvie, Karla
Rozenblatt-Rosen, Orit
Rodig, Scott
Chen, Fei
Wagle, Nikhil
Regev, Aviv
Klughammer, Johanna https://orcid.org/0000-0002-3628-9278
-
Funding
Funding for this research was provided by:
National Institute of Health (HHSN261201500003I, R33CA246455)
Deutsche Forschungsgemeinschaft (MA 9108/1-1)
Human Frontier Science Program (LT000452/2019-L)
EKFS (2019_A70)
Israel Science Foundation (ISF 2802/22)
Ludwig-Maximilians-Universität München
- License Information
-
More Information
Article History
Received: 31 October 2022
Accepted: 8 April 2025
First Online: 2 May 2025
Declarations
:
: All MBC samples used in this study underwent IRB review and approval at Dana Farber Cancer Institute (DFCI) (protocol 05–246) as well as at the Broad Institute (protocol #15 - 370B). All other data have been produced and published by others.
: Not applicable.
: A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and was an SAB member of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics, and Asimov until July 31, 2020. O.R.R., N.W., and A.R. are employees of Genentech from October 19, 2020, February 1, 2023, and August 1, 2020, respectively, and have equity in Roche. O.R.R. and A.R. are named inventors on multiple patents filed by the Broad Institute in the area of single cell and spatial genomics. S.R. has received research support from KITE/Gilead and Bristol-Myers-Squibb and is on the SAB of Immunitas Therapeutics.
